Replies to post #1093 on Rich Pharmaceuticals Inc. (fka RCHA)

[MR.METICULOUS]

nadia, you are posting old news from July 13, 2013....It's Feb. 4 2015!!

Big things have happened since then!!

WX:NYSE is where RCHA had completed its GMP clinical batch of RP-323 study drug that was manufactured at the WX:NYSE state-of-the-art facility. RCHA is the company that developed the new formulation and all regulatory required testing methods in 2014, but RCHA transferred the proprietary technology ”successfully" to WX:NYSE for the GMP production of RP-323. This is huge.

Also, WX:NYSE is expected to generated approximately $674 Million in Revenues and to deliver profitability in the area of $1.56 to $1.87 EPS (Earnings Per Share) I bring this point up because I am confident that the due diligence for a company of this magnitude believe this much in RCHA, then I must humble myself and any DD that I think is worthy of passing any kind of negative judgment on this company’s future.

http://ir.wuxiapptec.com/phoenix.zhtml?c=212698&p=irol-IRHome



Quote:

http://ir.wuxiapptec.com/phoenix.zhtml?c=212698&p=irol-newsArticle&ID=2005433

SHANGHAI , Jan. 9, 2015 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has updated its 2014 financial guidance. The company expects to achieve total revenues for full-year 2014 of approximately $674 million, compared to previous guidance of $670-672 million. The company expects to achieve diluted EPS of approximately $1.87 (non-GAAP) and approximately $1.56 (GAAP), compared to previous guidance of 1.83-1.86 (non-GAAP) and $1.55-1.58 (GAAP).

[Long-vestor]

This is who's running the scam in this, From the S-1 registration (S-1 is an immediate registration where there's no holding period) It's a 4 million dollar toxic dump spree!!

The purchase price per share to be paid by Macallan shall be calculated as a thirty five percent (35%) discount to the lesser of: (1) the lowest traded price of the Company Common Stock during the ten (10) consecutive trading days prior to the date the Drawdown Notice was submitted or

That's dump price @ 35% discount off of .0008 = 0.00052!!!


(the “Macallan Investment Agreement”). The Macallan Investment Agreement permits us to “put” up to $4,000,000 in shares of our common stock to Macallan over a period of up to thirty-six (36) months.

We are currently authorized to issue 37,503,000,000 shares of our common stock. We may be required to increase our authorized shares in order to receive the entire purchase price. Macallan has agreed to refrain from holding an amount of shares which would result in Macallan owning more than 4.99% of the then-outstanding shares of our common stock at any one time.


And this is when SEC allowed it:
NOTICE OF EFFECTIVENESS

Effective Date:
October 03, 2014

Form:
S-1